

Keyword index

1,2,4-triazole, 637
 1,2-diarylethaneimidazole, 143
 1,3-dioxolane, 637
 1,4-benzodioxan derivatives, 529
 1-carbamoyl-4-methyleneaminoxazetidinone derivative, 889
 1-oxa-3,8-diazaspiro[4.5]decan-2-one, 27
 2-acetylbutyrolactone, 815
 2-alkyloxy-adenosine, 505
 2-aminodiphenylsulfide, 39
 2-aralkyloxy-adenosine, 505
 3-alkylpiperidine, 205
 3-aminoflavone, 71
 3-D electronic structure descriptor, 505
 3-nitroflavone, 71
 3-piperidinol derivative, 231
 4,5-dihydro-4-oxo-3*H*-imidazo[4,5-*c*]pyridine, 479
 (4-acylpyrrol-2-yl)alkanoic acid, 805
 4-chloro-3-(2-chlorethyl)-2-methylquinoline, 815
 4-quinolone, 547
 5-HT_{1A} affinity, 795
 5-HT_{1A} agonist, 571
 5-HT_{1A} antagonist, 651
 5-HT_{1A}/D₂ α ligand, 739
 5-HT_{1D} receptor agonist, 129
 5-HT_{2A} receptor affinity, 651
 5-HT_{2C} receptor, 253
 5-HT-3 receptor antagonist, 385
 5-lipoxygenase, 895
 13-*tert*-butyl-ergoline, 795

A

α_1 and 5HT_{1A} receptor, 339
 α_1 -adrenoceptor subtype affinity, 9
 α -adrenoceptor agonist, 881
 α -adrenoceptor antagonist, 9
 α -methoxyoxime, 365
 α -(*N*)-acetylheteroarene derivative, 397
 α -trinositol, 535
 A₁-adenosine agonist, 505
 A₂-adenosine agonist, 505
 A_{2A}-adenosine receptor antagonist, 709
 ab initio calculation, 721
 acetogenin of Annonaceae, 617
 acyclovir, 3
 acylsulfonamide, 547
 adenosine antagonist, 493
 adenosine receptor, 709
 adrenergic α -stimulating activity, 231
 adrenergic activity, 103
 agonist, 59, 767
 Albatrellus ovinus, 351
 alkoxylfurocoumarine, 103
 (alkoxymethyl)alkyldimethylammonium chloride, 661

(alkylthiomethyl)alkyldimethylammonium chloride, 661
 AM1, 493
 amidines, 781
 aminogluthethimide, 901
 aminophylline, 175
 AMPA agonist, 329
 AMPA receptor, 329
 analgesia, 159
 analgesic activity, 195, 365, 535, 677
 angiotensin II, 747
 angiotensin II receptor antagonist, 479
 anilide, 129
 antagonist, 547, 767
 anthracenone, 895
 anthraquinone, 823
 antiemetic action, 27
 antiarrhythmic activity, 151
 antiasthmatic activity, 95
 anticancer, 823
 anticonvulsant activity, 365
 anticonvulsant, 583
 anticonvulsive action, 607
 antidepressant activity, 205
 antiestrogenic activity, 135
 antifungal activity, 1001
 antifungal activity, 637
 antifungal agent, 143
 antifungal compound, 901
 antihistamine activity, 95
 antihypertensive activity, 479
 antiinflammatory activity, 195, 321, 377, 529, 535, 677
 antiinflammatory compound, 365
 antimicrobial activity, 661
 antimicrobial screening, 759
 antimineralocorticoids, 869
 antineoplastic, 343
 antinociceptive, 843
 antioxidant, 625
 antioxidant activity, 377
 antipode, 159
 antiproliferative activity, 71, 895
 antiproliferative agent, 397
 antiprotazoan activity, 523
 antipsychotic, 739
 antipsychotic activity, 103
 aromatic sulfonamides, 445
 aryl propionic acid, 529
 arylazophenol, 583
 arylpiperazine, 339, 739
 aspirin, 987
 AT₁/AT₂ receptor subtype, 479
 atropine derivative, 595
 aza-inositol, 535
 azole, 143

B

β -adrenergic blockers, 955
 β -carboline alkaloids, 1009
 β -lactam monocyclic inhibitor, 889
 benextramine, 9
 benzamides, 385
 benzhydryloxyalkyl, 205
 benzimidazolone, 843
 benzodiazepine receptor, 607
 benzodiazepine receptor binding studies, 941
 benzofurancarboxylic acid, 425
 benzoic acid, 409
 benzopyran, 135
 bioactive conformation, 709
 biphenylsulfonamide, 479
 bombesin, 767
 bronchial secretion, 377
 bronchoconstriction, 843
 bronchodilator activity, 175
 butyrolactone, 617

C

cannabinoid, 165
 carbamate, 365
 carbazoles, 781
 carbonic anhydrase, 311, 445
 carbonic anhydrase, isozyme I, II, IV, 911
 cardiac ischaemia, 687
 cardiotoxic activity, 919
 carrageenin-induced oedema, 321
 carrier, 823
 catalepsy, 165
 CATALYSTTM, 279
 cellular electrophysiology, 357
 central benzodiazepine receptor, 83
 charge, 311
 chiral 1,8-naphthyridine derivatives, 955
 chirality, 263
 chloride current, 607
 chronotropic activity, 151
 clonogenic assay, 113
 cluster significance analysis, 493
 CNS, 351
 CNS activity, 583
 coanthracycline activity, 919
 CoMFA, 397
 confocal scanning laser microscopy (CSLM), 171
 conformation, 669
 conformational analysis, 231, 927
 coumaryloxyalkyl, 175
 Cu(II) complex, 901
 curcumin, 321, 625
 (cycloalkoxymethyl)alkyldimethylammonium chloride, 661
 cyclooxygenase, 159
 cyclooxygenase inhibition, 677

cytosolic phospholipase A₂, 805
 cytotoxic activity, 919, 1009
 cytotoxicity, 113, 583, 617

D

delta opioid receptor, 171
 deoxyacyclovir, 3
 diabetes, 453
 diaminoquinazoline, 9
 diaryldiamidines, 965
 dibenzylidenecyclohexanone, 625
 dibenzylidenecyclopentanone, 625
 dications, 781
 dihydropyridine, 151
 dipeptidyl peptidase IV, 301
 diphenylpentadienone, 625
 dithiazole, 759
 DNA, 781
 DNA, 965
 dopamine, 103
 dopamine D₁ receptor, 351
 dopamine transporter, 263
 drug design, 95
 dual antagonist, 95

E

E-isomer, 709
 elastase inhibitor, 219, 889
 enantiomer separation, 595
 enantioselectivity, 595
 endothelin antagonist, 425
 endothelin receptor antagonist, 515
 endothelin receptor ligand, 409
 enzymatic inhibition, 39
 EPS, 739
 ergoline derivative, 795
 excitatory amino acid, 329

F

fibrinogen receptor antagonist, 833
 flavone-8-acetic acid analog, 71
 fluorescent probe, 171
 future drugs, 687

G

γ -aminobutyric acid, 607
 GABA ratio, 83
 GABA_A antagonists, 357
 GABA_A partial agonists, 357
 GABA_A receptors, 357
 general anaesthetic, 731
 GHRP-2, 631
 GHRP-6, 631
 glycopeptide resistance, 459
 gonadotropin releasing hormone (GnRH), 927
 GP IIb/IIIa, 833
 Gram-positive bacteria, 459
 graphic computer model, 973
 growth hormone secretagogue, 631
 guanine derivative, 3

H

[³H]tyramine displacement, 53
 H₁-receptor, 95

HaCaT, 895

HEPT, 279

heterocyclic carboxyl bioisosteres, 357

HIV, 279

hydrazide-hydrazone, 753

hydrophobicity, 433

hydroxyurea resistant tumor, 397

hypothermia, 165

I

imidazo[1,2-*a*]pyrazine, 195
 imidazo[1,2-*a*]pyrimidines, 677
 imidazo[2,1-*b*]benzoxazole, 83
 imidazo[2,1-*b*]thiazole, 151
 imidazo[2,1-*b*]thiazolylmethylene-2-indolines, 919
 imidazole, 637, 1001
 iminoethers, 955
 in vitro agonism-antagonism profiles, 941
 in vitro asthma model, 95
 in vivo anticonvulsant evaluation, 941
 indole derivatives, 973
 inflammation, 159
 inhibitor, 805
 inositol phosphate, 535
 inotropic activity, 151
 insulin secretion, 453
 intercalator, 823
 iodine-125, 385
 irbesartan, 747
 isozymes I, II, IV, 445

K

ketopentanoic acid, 515
 kinetic study, 311

L

L-629,429, MK-0677, 631
 lethal toxicity, 433
 leukemia, 343
 leukemia L1210, 71, 113
 leukotriene D₄, 547
 leukotriene D₄ antagonist, 95
 lipid peroxidation, 625
 lipophilicity, 53, 1001
 LUMO, 311

M

Mannich base, 583
 mechanism, 731
 melphalan, 343
 mesolimbic selectivity, 103
 metronidazole, 995
 migraine, 129
 model evaluation, 571
 model of interaction, 721
 modeling, 59
 molecular dynamics, 219, 669
 molecular graphics, 927
 molecular model, 231
 molecular modeling, 39, 219, 547
 molecular pharmacology, 357
 multi-resistant pathogen, 459
 muscarinic antagonism, 595
 mutagenesis, 583

N

N-benzylisoquinuclidine, 377
 N⁹-benzyl- and N⁹-methyl-derivatives, 1009
 naltrindole derivative, 171
 naphthoimidazolidiones, 523
 naphthothiazole, 739
 naphthoxyalkyl, 175
 neural Ca²⁺-uptake inhibition, 27
 neural network, 279
 neurokinin receptors, 973
 nifedipine, 151
 nitroimidazole, 637
 NK₁, 843
 NMR structure, 669
 non-peptidic Ang II antagonist, 747

O

organotin, 123
 oxa-inositol, 535

P

P2 receptor, 183
para-substituted *N,N*-((dimethylamino)ethyl]-benzoate hydrochlorides, 433
 partial agonist, 253, 607, 767
 partition coefficient, 3
 PBR ligand, 241
 peripheral benzodiazepine receptor, 83, 241
 photodynamic therapy, 21
 photofrin, 21
 photoinactivate, 21
 physicochemical description, 571
 physicochemical parameters, 433
 platelet aggregation, 833
 platinum, 823
 PLS, 571
 PLS model, 219
Pneumocystis carinii pneumonia, 781, 965
 polyazol-1-ylmethyl, 637
 polyhydroxyalkyl derivatives, 1009
 positron emission tomography, 747
 post-coital contraceptive, 135
 potential cytotoxic agent, 815
 prazosin, 9
 prenylamine analogue, 53
 prodrugs, 987, 995
 proline peptidase, 301
 protease inhibitor, 301
 pseudopeptide, 767
 psychiatric disorder, 253
 purine receptor, 183
 pyrazinoindole, 253
 pyridazinone derivative, 339
 pyridinium salt, 911
 pyrido[3,2-*b*]carbazole, 113
 pyrimidine receptor, 183
 pyrimido[1,2-*a*]benzimidazole, 83
 pyrimido[2,1-*b*]benzoxazole, 83
 pyrrolidine, 301
 pyrrolo[2,1-*d*][1,5]benzothiazepine, 241
 pyrrolo[2,1-*d*][1,5]benzothiazocine, 241
 pyrylium salt, 911

Q

QSAR analysis, 493
 QSAR, 311, 433, 505, 571, 731
 quantitative structure-activity relationship, 53

R

(*R*)- and (*S*)-4'-hydroxy- Δ^9 -tetrahydrocannabinol, 165
 rat brain, 385
 receptor binding, 103, 329
 receptor subunits, 357
 recombinant receptors, 357
 Rekker approach, 3
 remodeling, 687
 reverse transcriptase, 279
 reversible MAO-B inhibition, 721
 RGD, 833
 rhodanine, 759
 rough sets method, 661
 RPLC method, 3

S

Σf -value, 3
 $[^{35}\text{S}]\text{TBPS}$ binding, 83
 Schiff base, 445
 selectivity, 795
 sensitizer, 21
 serine protease, 301
 serotonin, 59, 103, 129, 253
 shape similarity, 731
 singlet oxygen quantum yield, 21
 S_{RXI} , 523
 stereochemistry, 881
 stereoconversion, 159
 stereoselective synthesis, 1009
 steroids, 869

structure-activity relationship, 263, 339, 515, 805, 869, 1001
 structure-activity studies, 329, 357
 styrylxanthine, 709
 subtype selectivity, 595
 sulfonamidonitroethylene, 453
 sulfonyl halides, 901
 sulfonylcyanoguanidine, 453
 Sumatriptan, 129
 surfactant secretion, 377
 synthesis, 651, 709, 759

T

tachykinin, 843
 TCP/BTCP/PCP receptor, 263
 TET edema, 27
 tetraamin disulfide, 9
 tetraazoporphyrin, 21
 tetrahydro-4(3*H*)-quinazolinone, 651
 $[\text{tetrazoyl-}^{11}\text{C}]$ (SR47436/BMS-186295), 747
 theophylline, 175
 thermodynamics, 493
 thiazolidinone, 753
 thiazolo[4,5-*d*]pyrimidine, 759
 thiazolyl and benzothiazolyl hydrazone, 397
 thio derivative, 123
 thiosemicarbazide, 753
 thiourea, 631
 triazine, 123
 triazole, 911
 tributyltin, 385

triprenyl phenol, 351
 trypanocidal activity, 123
 trypanosomatid, 39
 trypanothione reductase, 39
 TSARTM, 279
 Tyr-bradykinin, 669
 $[\text{Tyr}(\text{Ome})^5]\text{GnRH}$, 927

U

ulcerogenic activity, 195, 677
 uptake inhibitor, 205
 urinary incontinence, 881
 uroselectivity, 881

V

van der Waals volume, 505
 variable mapping, 869
 vascular endothelium, 687
 vasodilator activity, 515
 verapamil, 151
 vesicular transport, 53
 Vilsmeier, 895

W

Wittig reaction, 1009

X

X-ray crystallography, 357, 583
 xanthine, 709

Z

Z-isomer, 709